全文获取类型
收费全文 | 11827篇 |
免费 | 721篇 |
国内免费 | 16篇 |
专业分类
耳鼻咽喉 | 54篇 |
儿科学 | 445篇 |
妇产科学 | 323篇 |
基础医学 | 1481篇 |
口腔科学 | 75篇 |
临床医学 | 2147篇 |
内科学 | 1973篇 |
皮肤病学 | 110篇 |
神经病学 | 1011篇 |
特种医学 | 242篇 |
外科学 | 1025篇 |
综合类 | 134篇 |
一般理论 | 8篇 |
预防医学 | 1752篇 |
眼科学 | 104篇 |
药学 | 696篇 |
中国医学 | 7篇 |
肿瘤学 | 977篇 |
出版年
2023年 | 59篇 |
2022年 | 107篇 |
2021年 | 184篇 |
2020年 | 118篇 |
2019年 | 186篇 |
2018年 | 241篇 |
2017年 | 221篇 |
2016年 | 190篇 |
2015年 | 220篇 |
2014年 | 365篇 |
2013年 | 569篇 |
2012年 | 817篇 |
2011年 | 896篇 |
2010年 | 500篇 |
2009年 | 451篇 |
2008年 | 776篇 |
2007年 | 876篇 |
2006年 | 841篇 |
2005年 | 914篇 |
2004年 | 912篇 |
2003年 | 845篇 |
2002年 | 770篇 |
2001年 | 92篇 |
2000年 | 68篇 |
1999年 | 109篇 |
1998年 | 144篇 |
1997年 | 126篇 |
1996年 | 98篇 |
1995年 | 80篇 |
1994年 | 79篇 |
1993年 | 92篇 |
1992年 | 56篇 |
1991年 | 57篇 |
1990年 | 48篇 |
1989年 | 25篇 |
1988年 | 39篇 |
1987年 | 25篇 |
1986年 | 28篇 |
1985年 | 31篇 |
1984年 | 46篇 |
1983年 | 33篇 |
1982年 | 44篇 |
1981年 | 36篇 |
1980年 | 32篇 |
1979年 | 19篇 |
1978年 | 13篇 |
1977年 | 17篇 |
1974年 | 9篇 |
1973年 | 8篇 |
1972年 | 9篇 |
排序方式: 共有10000条查询结果,搜索用时 0 毫秒
81.
Cohen D 《Current psychiatry reports》2000,2(1):32-39
Families have always cared for relatives with dementia, but scientific advances in diagnosis, management, and treatment will
make caring more challenging as more people are diagnosed in early stages and more live longer in severe stages with better
health care. This paper discusses the increasing prevalence, the economic value and cost of caregiving, the impact of caregiving
in families with and without dementia, the subjective experience of dementia and quality of life, the ethical challenges of
clinician-family partnerships, the complexity of family systems and processes that impact care patterns, homicide-suicide
in caregiving, long-term care staff training, and theoretic models. 相似文献
82.
Dietary carotenoids and risk of lung cancer in a pooled analysis of seven cohort studies. 总被引:5,自引:0,他引:5
Satu M?nnist? Stephanie A Smith-Warner Donna Spiegelman Demetrius Albanes Kristin Anderson Piet A van den Brandt James R Cerhan Graham Colditz Diane Feskanich Jo L Freudenheim Edward Giovannucci R Alexandra Goldbohm Saxon Graham Anthony B Miller Thomas E Rohan Jarmo Virtamo Walter C Willett David J Hunter 《Cancer epidemiology, biomarkers & prevention》2004,13(1):40-48
Intervention trials with supplemental beta-carotene have observed either no effect or a harmful effect on lung cancer risk. Because food composition databases for specific carotenoids have only become available recently, epidemiological evidence relating usual dietary levels of these carotenoids with lung cancer risk is limited. We analyzed the association between lung cancer risk and intakes of specific carotenoids using the primary data from seven cohort studies in North America and Europe. Carotenoid intakes were estimated from dietary questionnaires administered at baseline in each study. We calculated study-specific multivariate relative risks (RRs) and combined these using a random-effects model. The multivariate models included smoking history and other potential risk factors. During follow-up of up to 7-16 years across studies, 3,155 incident lung cancer cases were diagnosed among 399,765 participants. beta-Carotene intake was not associated with lung cancer risk (pooled multivariate RR = 0.98; 95% confidence interval, 0.87-1.11; highest versus lowest quintile). The RRs for alpha-carotene, lutein/zeaxanthin, and lycopene were also close to unity. beta-Cryptoxanthin intake was inversely associated with lung cancer risk (RR = 0.76; 95% confidence interval, 0.67-0.86; highest versus lowest quintile). These results did not change after adjustment for intakes of vitamin C (with or without supplements), folate (with or without supplements), and other carotenoids and multivitamin use. The associations generally were similar among never, past, or current smokers and by histological type. Although smoking is the strongest risk factor for lung cancer, greater intake of foods high in beta-cryptoxanthin, such as citrus fruit, may modestly lower the risk. 相似文献
83.
Deborah P Waber Lewis B Silverman Lori Catania William Mautz Montse Rue Richard D Gelber Donna E Levy Meredith A Goldwasser Heather Adams Annie Dufresne Victoria Metzger Ivonne Romero Nancy J Tarbell Virginia Kimball Dalton Stephen E Sallan 《Journal of clinical oncology》2004,22(13):2701-2707
PURPOSE: We evaluated 8-year survival and late neuropsychologic toxicity in children with acute lymphoblastic leukemia treated in a randomized clinical trial to test whether hyperfractionated (twice daily) cranial radiation therapy (CRT) can reduce incidence and severity of late toxicities associated with 18 Gy of CRT. PATIENTS AND METHODS: Between 1987 and 1995, 369 children treated on two consecutive Dana-Farber Cancer Institute Consortium protocols for high-risk acute lymphoblastic leukemia were randomly assigned to conventionally fractionated CRT (CFX) or hyperfractionated CRT (HFX) to a total dose of 18 Gy. Neuropsychologic testing was completed for 125 of 287 children in continuous complete remission. Event-free and overall survival, as well as neuropsychologic function, were compared for the two arms of the protocol. RESULTS: Eight-year event-free survival (+/- SE) was 80% +/- 3% for children randomly assigned to CFX and 72% +/- 3% for HFX (P =.06). Overall survival was 85% +/- 3% for CFX and 78% +/- 3% for HFX (P =.06). CNS relapses occurred in 2.8% of patients receiving CFX and 2.7% receiving HFX (P =.99). Cognitive function for both groups was solidly in the average range, with no group differences in intelligence, academic achievement, visuospatial reasoning, or verbal learning. Children on the HFX arm exhibited a modest advantage for visual memory (P <.05). CONCLUSION: HFX provides no benefit in terms of cognitive late effects and may compromise antileukemic efficacy. HFX should not be substituted for conventionally dosed CRT in children who require radiation therapy for treatment of acute lymphoblastic leukemia. 相似文献
84.
Wen Qing Yang Xueqing Lun Cheryl Ann Palmer M Elizabeth Wilcox Huong Muzik Zhong Qiao Shi Richard Dyck Matt Coffey Brad Thompson Mark Hamilton Sandra G Nishikawa Penny M A Brasher Kevin Fonseca David George N Berry Rewcastle Randal N Johnston Doug Stewart Patrick W K Lee Donna L Senger Peter A Forsyth 《Clinical cancer research》2004,10(24):8561-8576
PURPOSE: Human reovirus type 3 has been proposed to kill cancer cells with an activated Ras signaling pathway. The purpose of this study was to investigate the efficacy of reovirus in immunocompetent glioma animal models and safety/toxicity in immunocompetent animals, including nonhuman primates. EXPERIMENTAL DESIGN: Racine glioma cells 9L and RG2 were implanted s.c. or intracranially in Fisher 344 rats with or without reovirus antibodies, followed by treatment of reovirus. To study whether reovirus kills contralateral tumors in the brain and to determine viral distribution, we established an in situ dual tumor model followed by reovirus intratumoral inoculation only into the ipsilateral tumor. To evaluate neurotoxicity/safety of reovirus, Cynomolgus monkeys and immunocompetent rats were given intracranially with reovirus, and pathological examination and/or behavioral studies were done. Viral shedding and clinical biochemistry were systematically studied in monkeys. RESULTS: Intratumorally given reovirus significantly suppressed the growth of both s.c. and intracranially tumors and significantly prolonged survival. The presence of reovirus-neutralizing antibodies did not abort the reovirus' antitumor effect. Reovirus inhibited glioma growth intracranially in the ipsilateral but not the contralateral tumors; viral load in ipsilateral tumors was 15 to 330-fold higher than the contralateral tumors. No encephalitis or behavioral abnormalities were found in monkeys and rats given reovirus intracranially. No treatment-related clinical biochemistry changes or diffuse histopathological abnormality were found in monkeys inoculated intracranially with Good Manufacturing Practice prepared reovirus. Microscopic changes were confined to the region of viral inoculation and were dose related, suggesting reovirus intracranially was well tolerated in nonhuman primates. CONCLUSIONS: These data show the efficacy and safety of reovirus when it is used in the treatment of gliomas in immunocompetent hosts. Inoculation of reovirus into the brain of nonhuman primates did not produce significant toxicities. 相似文献
85.
Patricia A Ganz Carol M Moinpour Donna K Pauler Alice B Kornblith Ellen R Gaynor Stanley P Balcerzak Gretchen S Gatti Harry P Erba Sheryl McCoy Oliver W Press Richard I Fisher 《Journal of clinical oncology》2003,21(18):3512-3519
PURPOSE: We describe the short and intermediate-term quality-of-life (QOL) outcomes in patients treated on a randomized clinical trial in early-stage Hodgkin's disease (Southwest Oncology Group [SWOG] 9133) comparing subtotal lymphoid irradiation (STLI) with combined-modality treatment (CMT). PATIENTS AND METHODS: Two hundred forty-seven patients participated in the QOL study (SWOG 9208), completing several standardized instruments (Symptom Distress Scale; Cancer Rehabilitation Evaluation System - Short Form; Medical Outcomes Study 36-Item Short-Form Health Survey Vitality Scale; and a health perception item), as well as questions about work, marital status, and concerns about having children. This article reports on results from baseline before random assignment, at 6 months, and at 1 and 2 years after random assignment. RESULTS: Patients receiving CMT experienced significantly greater symptom distress (P <.0001), fatigue (P =.001), and poorer QOL (P =.015) at 6 months than the STLI patients, reflecting a shorter time since completion of therapy in the CMT arm. Importantly, patients in the two groups did not differ on any outcomes at the 1-and 2-year assessments. Both patient groups reported significantly more fatigue before treatment than healthy reference populations, and fatigue did not improve in either group after treatment. CONCLUSION: This study demonstrated that patients with early-stage Hodgkin's disease experience a short-term decrease in QOL and an increase in symptoms and fatigue with treatment, which is more severe with CMT; by 1 year, however, CMT and STLI patients report similar outcomes. Fatigue scores for both arms were lower at baseline than scores for the general population and did not return to normal levels 2 years after random assignment. The mechanisms responsible for this lingering problem warrant further investigation. 相似文献
86.
Ravi Salgia Thomas Lynch Arthur Skarin Joan Lucca Cathleen Lynch Ken Jung F Stephen Hodi Michael Jaklitsch Steve Mentzer Scott Swanson Jean Lukanich Raphael Bueno John Wain Douglas Mathisen Cameron Wright Panos Fidias Dean Donahue Shirley Clift Steve Hardy Donna Neuberg Richard Mulligan Iain Webb David Sugarbaker Martin Mihm Glenn Dranoff 《Journal of clinical oncology》2003,21(4):624-630
PURPOSE: We demonstrated that vaccination with irradiated tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (GM-CSF) stimulates potent, specific, and long-lasting antitumor immunity in multiple murine models and patients with metastatic melanoma. To test whether this vaccination strategy enhances antitumor immunity in patients with metastatic non-small-cell lung cancer (NSCLC), we conducted a phase I clinical trial. PATIENTS AND METHODS: Resected metastases were processed to single-cell suspension, infected with a replication-defective adenoviral vector encoding GM-CSF, irradiated, and cryopreserved. Individual vaccines consisted of 1 x 10(6), 4 x 10(6), or 1 x 10(7) cells, depending on overall yield, and were administered intradermally and subcutaneously at weekly and biweekly intervals. RESULTS: Vaccines were successfully manufactured for 34 (97%) of 35 patients. The average GM-CSF secretion was 513 ng/10(6) cells/24 h. Toxicities were restricted to grade 1 to 2 local skin reactions. Nine patients were withdrawn early because of rapid disease progression. Vaccination elicited dendritic cell, macrophage, granulocyte, and lymphocyte infiltrates in 18 of 25 assessable patients. Immunization stimulated the development of delayed-type hypersensitivity reactions to irradiated, dissociated, autologous, nontransfected tumor cells in 18 of 22 patients. Metastatic lesions resected after vaccination showed T lymphocyte and plasma cell infiltrates with tumor necrosis in three of six patients. Two patients surgically rendered as having no evidence of disease at enrollment remain free of disease at 43 and 42 months. Five patients showed stable disease durations of 33, 19, 12, 10, and 3 months. One mixed response was observed. CONCLUSION: Vaccination with irradiated autologous NSCLC cells engineered to secrete GM-CSF enhances antitumor immunity in some patients with metastatic NSCLC. 相似文献
87.
J. F. Cleary Rhoda Arzoomanian Donna Alberti Chris Feierabend Barry Storer Pauline Witt P. P. Carbone George Wilding 《Cancer chemotherapy and pharmacology》1997,39(4):300-306
Purpose: The activity of 5-fluorouracil (5-FU) against colon cancer is enhanced by leucovorin and the combination of 5-FU and levamisole
has activity in the adjuvant treatment of colonic malignancies. The combination of 5-FU with both leucovorin and levamisole
may provide additional benefit in the treatment of colon cancer. Methods: A phase I study to assess qualitative and quantitative toxicities of this three-drug combination and to determine a dose
for further phase II testing was undertaken. The role of levamisole as an immunomodulator was also assessed. Results: A group of 38 patients with incurable etastatic malignancies received 119 cycles of treatment at eight dose levels. 5-FU
(375 mg/m2 per day) and leucovorin (200 mg/m2 per day) were administered intravenously (days 1–5). Levamisole was administered orally (days 1–3 and 15–17) at doses from
30 to 470 mg/m2 per day. Patients received both 5FU/leucovorin and 5-FU/leucovorin/levamisole in random order for their initial two cycles.
All subsequent treatments were with the three-drug combination. Toxicities included nausea, vomiting, stomatitis, thrombocytopenia
and granulocytopenia. Diarrhea was the dose-limiting toxicity at 470 mg/m2 per day levamisole. The addition of levamisole resulted in more toxicity than 5-FU and leucovorin alone. No clinical responses
were seen with this regimen. The addition of levamisole resulted in more immunomodulation than 5-FU and leucovorin alone as
evidenced by release of neopterin from monocytes. Conclusion: With this schedule and dose of 5-FU and leucovorin, the maximum tolerated dose of levamisole was 354 mg/m2. However, given the lack of response and the absence of dose-dependent immunomodulation, this may not be the appropriate
dose for further phase 11 studies.
Received: 20 October 1995 / Accepted: 16 June 1996 相似文献
88.
89.
Hellman Richard Neuberg Donna S. Wagner Henry Grunnet Margaret Robins H. Ian Karp Daniel Flynn Patrick Adams George 《Journal of neuro-oncology》1998,37(1):55-62
This study is a combined modality Phase II therapeutic trial to determine the efficacy of the novel combination of VP-16, Vincristine and Procarbazine in addition to postoperative radiation therapy in patients with high grade intracranial gliomas. Thirty three patients (median age 51 years) were entered (27 with glioblastoma multiforme, 6 with anaplastic astrocytoma). Toxicity was manageable with no lethal toxicities. Five of seven life threatening toxicities were hematologic. Median overall survival was 14.2 months. These data suggest this regimen is effective treatment for patients with high grade gliomas. 相似文献
90.
Changes in the expression of the type-2 but not the type-1 cyclo-oxygenase enzyme in chorion-decidua with the onset of labour 总被引:3,自引:0,他引:3
Donna Slater Senior Research Fellow Victoria Allport Research Assistant Phillip Bennett Professor 《BJOG : an international journal of obstetrics and gynaecology》1998,105(7):745-748
Objective To determine the relative expression of cyclo-oxygenase (COX)-1 and COX-2 in the chorion-decidual part of human fetal membranes following delivery at term and to identify any changes in expression associated with labour.
Methods Fetal membranes were collected from 12 term pregnancies before labour following elective caesarean section and from 12 spontaneous vaginal deliveries. Expression of COX-1 and COX-2 mRNA was measured using a previously validated quantitative RT-PCR assay.
Results COX-2 expression exceeded that of COX-1 by approximately eight-fold. COX1 expression did not change but COX-2 expression was found to increase four-fold with labour.
Conclusions Chorion-decidua has the capacity to contribute to the increase in prostaglandin synthesis within the uterus associated with labour. As in the amnion, it is COX-2 and not COX-1 which is upregulated with labour. COX-2 selective anti-prostaglandins should therefore be as effective as nonselective drugs in inhibition of fetal membrane prostaglandin synthesis. 相似文献
Methods Fetal membranes were collected from 12 term pregnancies before labour following elective caesarean section and from 12 spontaneous vaginal deliveries. Expression of COX-1 and COX-2 mRNA was measured using a previously validated quantitative RT-PCR assay.
Results COX-2 expression exceeded that of COX-1 by approximately eight-fold. COX1 expression did not change but COX-2 expression was found to increase four-fold with labour.
Conclusions Chorion-decidua has the capacity to contribute to the increase in prostaglandin synthesis within the uterus associated with labour. As in the amnion, it is COX-2 and not COX-1 which is upregulated with labour. COX-2 selective anti-prostaglandins should therefore be as effective as nonselective drugs in inhibition of fetal membrane prostaglandin synthesis. 相似文献